-
-
-
-
-
-
-
Connect Biopharma reports new mechanism data for rademikibart drug
-
-
-
-
-
-
-
Connect Biopharma ends ADR program, lists ordinary shares on NASDAQ
-
-
-
-
-
-
-
Connect Biopharma (CNTB) Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
-
-
-
-
-
-
-
Connect Biopharma (CNTB) Appoints Barry Quart as CEO, David Szekeres as President
423,925 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

